research The Development of Oral Hairy Leukoplakia During JAK Inhibitor Baricitinib Therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
Search
for
Sort by
Research
60-90 / 1000+ results research Atopic Dermatitis And Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
research Improvement in Health-Related Quality of Life and Symptoms of Anxiety and Depression in Patients with Alopecia Areata Randomized to Baricitinib or Placebo: Results from Two International Randomized Controlled Trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
research An Update in the Management of Alopecia Areata
New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
research Overview Of Alopecia Areata For Managed Care And Payer Stakeholders In The United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
New understanding and treatments for hair loss are improving, but more research is needed.
research Visualizing Severity Of Alopecia Tool Scores In The Clinical Setting Using Patient Images From A Clinical Trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research Molecular Functional Analyses Revealed Essential Roles of HSP90 and Lamin A/C in Growth, Migration, and Self-Aggregation of Dermal Papilla Cells
HSP90 and lamin A/C are crucial for hair growth and could be targets for treating hair loss.
research Alopecia Areata: Multifactorial Disease Involving Genetic, Environmental, and Autoimmune Factors
Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
research Response to Baricitinib in the Treatment of Patients with Early and Late Onset Alopecia Areata in the Phase 2 Portion of BRAVE-AA1 Randomized Controlled Trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata Achieving Scalp Hair Regrowth: Results From Two Randomized Controlled Trials
Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
research Differentiating Between Central Centrifugal Cicatricial Alopecia, Traction Alopecia, and Alopecia Areata in Black Patients: Photographic Examples from a Clinical Trial
Visual signs are crucial for accurately diagnosing and treating different types of hair loss in Black patients.
research Hair Growth Under Dupilumab in Alopecia Areata Universalis and Atopic Dermatitis
Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
research Among Scalp Non-Responder Patients with Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment with Baricitinib Resulted in Meaningful Scalp Responses for Patients with Severe Alopecia Areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.